 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 查看: 3946 | 回復(fù): 16 | ||||
wachina至尊木蟲 (知名作家)
|
[交流]
武田fasiglifam (TAK-875)宣告失敗，恒瑞呋格列泛齒亡唇寒 已有16人參與
|
|||
|
Takeda terminates development activities for fasiglifam (TAK-875) Takeda Pharmaceutical Company Limited (Takeda) announced that it has decided voluntarily to terminate the development activities for fasiglifam (TAK-875), an investigational treatment for type 2 diabetes, due to concerns about liver safety. Patient safety is Takeda's highest priority. The company has worked with three independent panels of experts to provide for the safety of trial participants and ensure independent safety oversight for the clinical trials throughout the duration of the fasiglifam (TAK-875) Phase 3 development program. The expert panels include the independent Data Monitoring Committee (DMC), a committee that oversees the fasiglifam global clinical development program, reviews the unblinded clinical data from program trials and provides continual safety oversight of trial subjects and recommendations. The DMC is comprised of clinical experts in endocrinology, cardiology and hepatology as well as a statistician. The independent Liver Safety Evaluation Committee (LSEC) is comprised of five hepatologists with expertise in drug-induced liver injury. While remaining blinded to treatment information, the LSEC regularly evaluates data on liver enzymes elevations and adjudicates cases that impacted the liver. In addition, an independent Executive Committee (EC) provides additional oversight for the fasiglifam (TAK-875) cardiovascular outcomes trial. After careful consideration of the data emerging from all the clinical trials and in consultation with these panels, the company has reached the conclusion that, on balance, the benefits of treating patients with fasiglifam (TAK-875) do not outweigh the potential risks. For this reason, Takeda has decided voluntarily to terminate the development activities for fasiglifam. 作為慢性疾病：糖尿病的治療，肝毒性太致命了，難怪武田揮淚斬馬謖。值得一提的是，恒瑞也向CFDA申報了GPR-40激動劑呋格列泛，現(xiàn)在心里估計也是拔涼拔涼的 |
回復(fù)此樓» 收錄本帖的淘帖專輯推薦
 新藥仿藥 |
» 猜你喜歡
求購時間長一些的硝酸釷
已經(jīng)有0人回復(fù)
-
求助各位大佬，載藥PLGA納米粒易團(tuán)聚該如何解決？
已經(jīng)有0人回復(fù)
-
藥物學(xué)論文潤色/翻譯怎么收費(fèi)?
已經(jīng)有201人回復(fù)
-
透明質(zhì)酸 甲基丙烯酸酐
已經(jīng)有0人回復(fù)
-
305材料專碩調(diào)劑
已經(jīng)有12人回復(fù)
-
CSC改派-博士生交流訪學(xué)
已經(jīng)有19人回復(fù)
-
中山大學(xué)-第七醫(yī)院-招科研助理1名（基因設(shè)計和克隆、RNA合成）
已經(jīng)有0人回復(fù)
-
中山大學(xué)-第七醫(yī)院-招科研助理1名（基因設(shè)計和克隆、RNA合成）
已經(jīng)有1人回復(fù)
-
巴黎薩克雷大學(xué)與國家留學(xué)基金委合作博士研究生項目-脂質(zhì)納米藥物/生物材料/多酚遞送
已經(jīng)有10人回復(fù)
-
錦州醫(yī)科大學(xué)藥用生物材料（專業(yè)代碼1007Z1）招收調(diào)劑考生
已經(jīng)有0人回復(fù)
-
錦州醫(yī)科大學(xué)藥用生物材料（專業(yè)代碼1007Z1）招收調(diào)劑考生
已經(jīng)有1人回復(fù)
guri
鐵蟲 (初入文壇)
- 應(yīng)助: 0 (幼兒園)
- 金幣: 74
- 帖子: 6
- 在線: 9.6小時
- 蟲號: 2285814
- 注冊: 2013-02-18
- 性別: GG
- 專業(yè): 藥物設(shè)計與藥物信息
3樓2013-12-30 13:06:43
wph75623
銅蟲 (小有名氣)
- 應(yīng)助: 1 (幼兒園)
- 金幣: 159.9
- 帖子: 137
- 在線: 54.9小時
- 蟲號: 1922830
- 注冊: 2012-08-03
- 專業(yè): 合成藥物化學(xué)
4樓2013-12-30 16:49:55
mengdragon
木蟲 (著名寫手)
muchong
- 應(yīng)助: 61 (初中生)
- 金幣: 3372.3
- 散金: 54
- 紅花: 13
- 帖子: 1806
- 在線: 356.2小時
- 蟲號: 203914
- 注冊: 2006-03-02
- 性別: GG
- 專業(yè): 合成藥物化學(xué)
6樓2013-12-30 22:13:49
2樓2013-12-30 12:41:43
| 哎�。。。。。�！ |
5樓2013-12-30 17:02:55
091602
鐵桿木蟲 (小有名氣)
- 應(yīng)助: 65 (初中生)
- 金幣: 11932.2
- 散金: 9
- 紅花: 4
- 帖子: 203
- 在線: 2295.2小時
- 蟲號: 826350
- 注冊: 2009-08-12
- 性別: GG
- 專業(yè): 藥物合成
7樓2013-12-31 08:51:06
天使009
新蟲 (小有名氣)
- 應(yīng)助: 1 (幼兒園)
- 金幣: 317.4
- 帖子: 129
- 在線: 57.4小時
- 蟲號: 1449481
- 注冊: 2011-10-18
- 專業(yè): 金融學(xué)
8樓2013-12-31 09:35:56
lu198799
金蟲 (正式寫手)
- 應(yīng)助: 7 (幼兒園)
- 金幣: 1362.5
- 散金: 2
- 帖子: 454
- 在線: 127.5小時
- 蟲號: 775421
- 注冊: 2009-05-20
- 性別: GG
- 專業(yè): 合成藥物化學(xué)
9樓2013-12-31 10:00:56
gwmgyp
版主 (知名作家)
搬磚將
- DRDEPI: 8
- 應(yīng)助: 820 (博后)
- 貴賓: 3.006
- 金幣: 17161.9
- 散金: 13
- 紅花: 67
- 沙發(fā): 1
- 帖子: 5612
- 在線: 944.5小時
- 蟲號: 1272275
- 注冊: 2011-04-21
- 專業(yè): 藥物分析
- 管轄: 新藥研發(fā)
10樓2013-12-31 10:12:11
相關(guān)版塊跳轉(zhuǎn)
我要訂閱樓主 wachina 的主題更新
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 0703化學(xué)調(diào)劑 ，六級已過，有科研經(jīng)歷 +11 | 曦熙兮 2026-03-15 | 11/550 |
|
|---|---|---|---|---|
|
|
[考研] 085601材料工程專碩求調(diào)劑 +10 | 慕寒mio 2026-03-16 | 10/500 |
|
|
[考研] 266求調(diào)劑 +5 | 陽陽哇塞 2026-03-14 | 10/500 |
|
|
|
[考研] 材料與化工求調(diào)劑 +7 | 為學(xué)666 2026-03-16 | 7/350 |
|
|
|
[考研] 化學(xué)求調(diào)劑 +3 | 臨澤境llllll 2026-03-17 | 4/200 |
|
|
|
[教師之家] 焦慮 +9 | 水冰月月野兔 2026-03-13 | 13/650 |
|
|
|
[考研] 085700資源與環(huán)境308求調(diào)劑 +3 | 墨墨漠 2026-03-18 | 3/150 |
|
|
|
[考研] 344求調(diào)劑 +6 | knight344 2026-03-16 | 7/350 |
|
|
|
[考研] 297求調(diào)劑 +8 | 戲精丹丹丹 2026-03-17 | 8/400 |
|
|
|
[考研] 288求調(diào)劑，一志愿華南理工大學(xué)071005 +4 | ioodiiij 2026-03-17 | 4/200 |
|
|
|
[考博] 環(huán)境領(lǐng)域全國重點(diǎn)實(shí)驗(yàn)室招收博士1-2名 +3 | QGZDSYS 2026-03-13 | 5/250 |
|
|
|
[考研] 0703化學(xué)調(diào)劑 +3 | 妮妮ninicgb 2026-03-17 | 3/150 |
|
|
|
[考研] 334求調(diào)劑 +3 | 志存高遠(yuǎn)意在機(jī)?/a> 2026-03-16 | 3/150 |
|
|
|
[考研] 304求調(diào)劑 +5 | 素年祭語 2026-03-15 | 5/250 |
|
|
|
[考研] 304求調(diào)劑 +3 | 曼殊2266 2026-03-14 | 3/150 |
|
|
|
[考研] 321求調(diào)劑 +5 | 大米飯！ 2026-03-15 | 5/250 |
|
|
|
[考研] 本科南京大學(xué)一志愿川大藥學(xué)327 +3 | 麥田耕者 2026-03-14 | 3/150 |
|
|
|
[基金申請] 現(xiàn)在如何回避去年的某一個專家，不知道名字 +3 | zk200107 2026-03-12 | 6/300 |
|
|
|
[考研] 26調(diào)劑/材料科學(xué)與工程/總分295/求收留 +9 | 2026調(diào)劑俠 2026-03-12 | 9/450 |
|
|
|
[碩博家園] 085600 260分求調(diào)劑 +3 | 天空還下雨么 2026-03-13 | 5/250 |
|